Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Dipstick Technology Could Offer Faster, Cheaper and Mobile COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 07 Oct 2020
A new technology that helps to quickly extract and analyze genetic material could be used for cheap, accurate and mobile COVID-19 testing, including at airports and remote testing centers.

‘Dipstick’ technology, developed by the University of Queensland (Queensland, Australia) allows genetic material to be extracted in as little as 30 seconds, with a full molecular diagnosis in 40 minutes. More...
The process can be used to extract genetic material from most living organisms, including people, livestock, bacteria and viruses. The researchers have already applied the technology in other areas, primarily to fight plant pathogens. According to the team, their dipsticks can be produced quickly, cheaply and in bulk using a household pasta maker.

“Our dipstick tech is incredibly cheap and can be used virtually anywhere, without the need for specialized equipment or a laboratory,” said Professor Jimmy Botella of the University of Queensland. “Our tech enables the purification of DNA and RNA nucleic acids from patient samples - a critical step in COVID-19 diagnosis.”

“Combined with a portable diagnostic machine we’ve developed - which fits in your hand and can be powered by a car’s cigarette lighter connection - we could enable faster identification and isolation of positive patients, helping to reduce the spread of the disease,” added Botella. “We’re hoping it will be used to expand COVID-19 diagnostic testing to non-laboratory environments such as airports, remote testing centers and GP clinics.”

Related Links:
University of Queensland


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.